Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.15
-0.0500-1.56%
Post-market: 3.160.0100+0.32%19:06 EDT
Volume:4.05M
Turnover:12.71M
Market Cap:611.10M
PE:-4.14
High:3.20
Open:3.20
Low:3.09
Close:3.20
52wk High:6.44
52wk Low:2.56
Shares:194.00M
Float Shares:164.00M
Volume Ratio:0.72
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7600
EPS(LYR):-0.9999
ROE:-28.87%
ROA:-17.20%
PB:1.29
PE(LYR):-3.15

Loading ...

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

GlobeNewswire
·
Yesterday

ALT Co. to Host Non-Deal Roadshow for Q2 2026 Results in Seoul

TIPRANKS
·
Aug 20

NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer

Reuters
·
Aug 15

Altimmune CEO Jerome Benedict Durso Acquires USD 44,250 in Common Shares

Reuters
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

TIPRANKS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Altimmune (ALT) and HCA Healthcare (HCA)

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Altimmune Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Altimmune Rises on Smaller-than-Expected Quarterly Loss

Reuters
·
Aug 12

Altimmune Posts Smaller-than-Expected Q2 Net Loss Per Share

Reuters
·
Aug 12

Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate

Benzinga Earnings
·
Aug 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

Altimmune Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Bitcoin holds a resistance break as gold surges and ALT risk builds

Kitco
·
Aug 06

Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH

MT Newswires Live
·
Aug 03

Altimmune - 52-Week Data Readout from Performa Phase 3 Trial Anticipated in 2029

THOMSON REUTERS
·
Aug 03

Altimmune Initiates Performa Phase 3 Trial of Pemvidutide in Patients with Mash

THOMSON REUTERS
·
Aug 03

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

GlobeNewswire
·
Jul 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)

TIPRANKS
·
Jul 29

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29